Loading... Please wait...
Sort by:


dossier-jpg.jpgDossier 
reports present unbiased and concise analysis based on interviews with leading industry experts on important trends and challenging issues affecting the pharma industry today. 

  • The Future of Virtual Healthcare
    Learn More The Future of Virtual Healthcare
    What strategy should pharma be pursuing in virtual healthcare? Applications for virtual healthcare engagement are quickly evolving beyond websites and apps towards advanced tools such as virtual assistants and virtual...
  • The Impact of 5G on Healthcare
    Learn More The Impact of 5G on Healthcare
    Health insurance: how to thrive in an increasingly digital health world 5G wireless network technology has the potential to revolutionise pharma's business. Combined with advances in artificial intelligence and machine...
  • The Future of Key Account Management in Pharma
    Learn More The Future of Key Account Management in Pharma
    Are you ready for fundamental disruption to key account management practice? While the Key Account Management (KAM) role will continue to prioritise the development of long-term, sustainable partnerships between...
  • Trends in Investment by Big Pharma
    Learn More Trends in Investment by Big Pharma
    What direction are big pharma investments taking? The investment decisions made by the biggest players in core disease areas drive market trends—so it's crucial to understand where the big money is going and why...
  • Benchmarking Key Account Management Capabilities (2019)
    Learn More Benchmarking Key Account Management Capabilities (2019)
    What factors determine a Key Account Manager (KAM) team's size and structure? At what stage in a product's lifecycle are KAMs assigned and how many brands should a typical KAM support? What personal attributes and...
  • Biosimilars: The Importance of Real-World Evidence (2019)
    Learn More Biosimilars: The Importance of Real-World Evidence (2019)
    Are you generating the right RWE to influence the right stakeholders? As the biosimilar sector continues to evolve and experience of their use deepens, what role should real-world evidence (RWE) now take in stakeholder...
  • Real-World Data Capabilities: Benchmarking Pharma Companies (2019)
    Learn More Real-World Data Capabilities: Benchmarking Pharma Companies (2019)
    Are you fully and efficiently exploiting real-world data across your business? The impact of real-world data (RWD) is growing but few companies are fully exploiting its potential across all clinical and commercial areas...
  • Financing High-Cost Therapies through Reinsurance
    Learn More Financing High-Cost Therapies through Reinsurance
    Could reinsurance allay health insurers' fear about high cell and gene therapy costs? With the prospect of many cell and gene therapies coming to market in the medium term, often with record breaking list prices and...
  • Biosimilars: European Payer Insights (2019)
    Learn More Biosimilars: European Payer Insights (2019)
    As the European biosimilars market surges, what do payers see as the next steps? The approval in 2018 of biosimilar versions of adalimumab (Abbvie's Humira) and trastuzumab (Roche's Herceptin) is a major boost to the...
  • Paying for Gene Therapy: Payer Insights
    Learn More Paying for Gene Therapy: Payer Insights
    Payers caution pharma to think hard about price if they want support for their gene therapies The message from payers is stark: developers who present gene therapies with limited clinical data, eye wateringly high...
  • Orphan Drugs: Drivers of Market Growth (2019)
    Learn More Orphan Drugs: Drivers of Market Growth (2019)
    Orphan drugs: Building your profits or draining your resources? Substantial growth prospects in orphan drugs (more than double the overall pharma market) have enticed many pharma companies to enter the fray. But all...
  • Charting MSL Activity and Performance 2019
    Learn More Charting MSL Activity and Performance 2019
    Understand which MSL activities are seen as being most important in the US and Western Europe Benchmark your own MSL programmes and identify new ways to improve performance Identify the most widely-used performance...
  • Payer Engagement: Benchmarking Team Structure and Activity 2019
    Learn More Payer Engagement: Benchmarking Team Structure and Activity 2019
    Is your payer engagement team appropriately experienced and resourced? What are the drivers that influence payer engagement team size and structure? What are the emerging challenges payer engagement teams will face...
  • The Orphan Drug Fact File 2019
    Learn More The Orphan Drug Fact File 2019
    The Orphan Drugs Pipeline: Everything you need to know about current contenders and new opportunities By 2024, orphan drugs are expected to account for one fifth of worldwide prescription drug sales—some $242...
  • Trends in KOL Experience Management
    Learn More Trends in KOL Experience Management
    How well does your MSL KOL engagement activity compare to competitors? What tools are being used today to measure engagement with KOLs? How often are KOLs surveyed regarding satisfaction levels? Which metrics are...
  • KAM Metrics: Measuring Success (2019)
    Learn More KAM Metrics: Measuring Success (2019)
    Secure a successful future for your KAM teams by proving their true value KAM teams are still evolving but they're also concerned about their future. They need appropriate measures to demonstrate their true value...

customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved